Table 1 Demographic and baseline characteristics of the anemic and non-anemic patients
From: Post renal transplant anemia: severity, causes and their association with graft and patient survival
|  | Anemia | No anemia (n = 727) | Total (n = 1139) | ||
|---|---|---|---|---|---|
|  | Mild (n = 278) | Severe (n = 134) | All (n = 412) |  |  |
Mean age at transplant (mean ± SD) | 50.7 ± 15.8 | 45.9 ± 16.3 | 49.1 ± 16.1 | 47.5 ± 14.1 | 48.1 ± 14.9 |
Male sex n (%) | 60 (21.6) | 81 (60.4) | 141 (34.2) | 236 (32.5) | 377 (33.1%) |
BMI (Kg/m^2) | 26.7 ± 5 | 24.7 ± 6 | 26.1 ± 5.4 | 26 ± 4.8 | 26 ± 5 |
HCV positive n (%) | 3 (1.1) | 3 (2.4) | 6 (1.6) | 33 (4.5) | 39 (3.5) |
HBV positive n (%) | 4 (1.5) | 4 (3.2) | 8 (2.1) | 14 (1.9) | 22 (2) |
Donor CMV positive n (%) | 202 (77.1) | 93 (74.4) | 295 (76.2) | 592 (81.4) | 887 (79.6) |
Recipient CMV positive n (%) | 220 (84) | 111 (88.8) | 331 (85.5) | 647 (89) | 978 (87.8) |
Original renal disease | |||||
 Glomerulonephritis | 64 (20.9) | 42 (28.2) | 106 (23.3) | 227 (29.9) | 333 (26.6) |
 CAKUT | 37 (12.1) | 22 (17.5) | 59 (13) | 67 (8.4) | 126 (10.1) |
 Diabetic nephropathy | 72 (23.5) | 36 (24.2) | 108 (23.7) | 132 (16.6) | 240 (19.2) |
 Polycystic kidney disease (PKD) | 29 (9.5) | 12 (8.1) | 41 (9) | 102 (12.8) | 143 (11.4) |
 Genetic disease (excluding PKD) | 11 (3.6) | 4 (2.7) | 15 (3.3) | 18 (2.3) | 33 (2.6) |
 Chronic interstitial nephritis | 8 (2.6) | 4 (2.7) | 12 (2.6) | 13 (1.6) | 25 (2) |
 No diagnosis/unknown | 85 (27.8) | 29 (19.5) | 114 (25.1) | 238 (29.9) | 352 (28.1) |
Length of hospitalization (ln, days) | 2.4 ± 0.5 | 2.5 ± 0.6 | 2.4 ± 0.5 | 2.5 ± 0.5 | 2.4 ± 0.5 |
Mean duration of dialysis (months) | 32.8 ± 37.3 | 36.8 ± 45.7 | 34.1 ± 40.2 | 34.3 ± 38.4 | 34.2 ± 39 |
Previous renal transplantation n (%) | |||||
 0 | 255 (91.7) | 110 (82.1) | 365 (88.6) | 643 (88.4) | 1008 (88.5) |
 ≥1 | 23 (8.3) | 24 (17.9) | 47 (11.4) | 84 (11.6) | 131 (11.5) |
Living donor (%) | 167 (60.1) | 74 (55.2) | 241 (58.5) | 427 (58.7) | 668 (58.6) |
Mean donor age (years) | 48.9 ± 14.3 | 47 ± 14.6 | 48.3 ± 14.4 | 42.66 ± 13.9 | 44.7 ± 14.3 |
HLA Mismatch (mean ± SD) | 4.2 ± 1.6 | 4.2 ± 1.5 | 4.2 ± 1.6 | 4 ± 1.6 | 4.1 ± 1.6 |
Mean cold ischemia time (hours) | 5:06 ± 6:31 | 5:09 ± 7:08 | 5:07 ± 6:42 | 6:16 ± 7.56 | 5:52 ± 7.33 |
PRA > 10% (%) | 31 (11.2) | 22 (16.4) | 53 (12.9) | 79 (10.9) | 132 (11.6) |
Delayed graft function n (%) | 48 (17.3) | 31 (23.1) | 79 (19.2) | 124 (17.1) | 203 (17.8) |
Co-morbidities n (%) | |||||
 Diabetes | 96 (34.5) | 44 (32.8) | 140 (34) | 166 (22.8) | 306 (26.9) |
 Hypertension | 218 (86.2) | 100 (82.6) | 318 (85) | 610 (87.3) | 928 (86.5) |
 Cardiovascular | 76 (27.3) | 30 (22.4) | 106 (25.7) | 123 (16.9) | 229 (20.1) |
Laboratory workup at 6 months: | |||||
 eGFR (ml/min/1.73 m^2) | 55.8 ± 19.6 | 52.3 ± 22.7 | 54.7 ± 20.7 | 63.3 ± 19.5 | 60.2 ± 20.3 |
 Mean Hemoglobin (g/dL) | 12.1 ± 1.1 | 10.15 ± 1.5 | 11.7 ± 1.4 | 13.4 ± 1.7 | 12.8 ± 1.8 |
 Hematocrit (%) | 37.1 ± 3.6 | 33.9 ± 4.7 | 36.1 ± 4.3 | 41.1 ± 5.2 | 39.2 ± 5.4 |
 MCV (fL) | 87.7 ± 6.4 | 87.2 ± 7.9 | 87.5 ± 6.9 | 88.3 ± 5.8 | 88 ± 6.3 |
 RDW (%) | 14.5 ± 1.5 | 14.7 ± 1.5 | 14.6 ± 1.5 | 14.3 ± 1.2 | 14.4 ± 1.3 |
 Platelets (X10^3/microL) | 196.5 ± 68.1 | 229.8 ± 90.5 | 207.3 ± 77.5 | 208.7 ± 65.4 | 208.2 ± 70.1 |
 Leukocytes (X10^3/microL) | 6.4 ± 2.2 | 6.7 ± 3.4 | 6.5 ± 2.6 | 7.4 ± 2.6 | 7 ± 2.7 |
 Iron (microgram/dL) | 71.2 ± 34.4 | 63.7 ± 35.9 | 68.1 ± 35.2 | 77.6 ± 36.9 | 72.9 ± 36.4 |
 Transferrin (mg/dL) | 219.2 ± 42.6 | 197.8 ± 59.1 | 210.3 ± 51.1 | 221.3 ± 49.9 | 215.8 ± 50.8 |
 Transferrin saturation (%) | 23.6 ± 13 | 24.8 ± 15.7 | 24.1 ± 14.2 | 25.7 ± 14.6 | 24.9 ± 14.4 |
 Ferritin (ng/mL) | 370.2 ± 393.2 | 461.4 ± 537 | 408.6 ± 460.1 | 388.8 ± 458.5 | 399.5 ± 458.8 |
 Albumin n (%) | 4.04 ± 0.5 | 4.02 ± 0.5 | 4.04 ± 0.5 | 4.15 ± 0.39 | 4.1 ± 0.45 |
 Folic acid (nmol/L) | 15.3 ± 9.7 | 15.9 ± 12.1 | 15.5 ± 10.6 | 16.7 ± 9.9 | 16.1 ± 10.2 |
 Vitamin B12 (pmol/L) | 474.7 ± 299.9 | 487.9 ± 284.1 | 479 ± 294.1 | 413.9 ± 213 | 16.1 ± 10.2 |
 FK506 level (ng/ml) | 8.4 ± 2.6 | 8.4 ± 3 | 8.4 ± 2.8 | 8.8 ± 3 | 8.7 ± 2.9 |
Immunosuppressive drugs | |||||
 Tacrolimus | 245 (93.5) | 110 (88) | 355 (91.7) | 661 (90.9) | 1016 (91.2) |
 Cyclosporine | 8 (3.1) | 9 (7.2) | 17 (4.4) | 31 (4.3) | 48 (4.3) |
 mTOR inhibitors | 6 (2.3) | 4 (3.2) | 10 (2.6) | 22 (3) | 32 (2.9) |
 Other | 3 (1.1) | 2 (1.6) | 5 (1.3) | 13 (1.8) | 18 (1.6) |
Erythropoietin treatment (%) | 7 (2.5) | 8 (5.9) | 15 (3.6) | 0 (0) | 15 (1.3) |